Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹1425.00

prior close

₹1432.50

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-1.7% vs market

Pharmaceuticals peers, median of 148sector+0.3%-2.0% vs sector

On the reaction day the stock moved 1.7 pts less than Nifty Smallcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.2

15m

-1.7

30m

-3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.1-1.7+0.3-2.0

Next day

-3.6-1.4-2.2-0.3-3.2

-2.7-0.9-1.8-0.2-2.5

-1.2-0.9-0.3-0.1-1.1

+2.1-0.3+2.4+0.2+1.9

+2.1-0.7+2.8-0.6+2.7

+3.4+1.4+2.0+0.2+3.1

15d

-3.3-0.2-3.1-1.2-2.1

-5.3+1.0-6.2-0.8-4.5

-1.3+1.7-3.0-0.5-0.8

-5.2+1.5-6.7-3.6-1.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Emcure Pharmaceuticals reported consolidated revenue of Rs. 2,101 crore for Q1FY26, up 15.7% year-on-year, driven by 9.4% growth in the domestic business (Rs. 995 crore) and 22.1% growth in the international business (Rs. 1,106 crore). EBITDA rose 20.1% to Rs. 404 crore with margins expanding to 19.2% from 18.5% a year ago. Profit after tax jumped about 41% to Rs. 215 crore. The company booked a Rs. 35 crore exceptional expense for a one-time legal settlement. Key subsidiaries Tillomed acquired Manx Healthcare's product portfolio for around Rs. 2,202 crore, and the board approved buying out minority shareholders in Zuventus Healthcare to make it wholly owned. Statutory auditors B S R & Co. LLP issued an unqualified limited review report on the results.

Likely market impact

Strong Q1 with double-digit revenue growth, margin expansion, and over 40% PAT growth signals healthy operational momentum, likely to be viewed positively by investors. The Zuventus buyout and expanded Sanofi partnership are incremental positives for the franchise.